Welcome to our dedicated page for ADMA BIOLOGICS SEC filings (Ticker: ADMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ADMA BIOLOGICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ADMA BIOLOGICS's regulatory disclosures and financial reporting.
ADMA Biologics, Inc. executive Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance, reported a Form 4 transaction involving company common stock. On February 19, 2026, 8,161 shares were withheld by the company at $16.32 per share to cover mandatory tax withholding on vesting restricted stock units, which is not an open market sale. After this tax-withholding disposition, she directly held 572,160 shares of common stock, reflecting prior option exercises and earlier RSU net settlements.
ADMA Biologics President and CEO Adam S. Grossman reported a Form 4 transaction where 24,793 shares of common stock were withheld on February 19, 2026 at $16.32 per share to cover mandatory tax obligations upon the vesting of restricted stock units. Footnotes clarify this was a tax-withholding disposition and not an open market sale.
After this transaction, Grossman directly owned 2,259,586 shares of ADMA common stock. He also had indirect ownership of additional shares, including positions held through Areth, LLC and Hariden, LLC, where he is a control person and managing member, respectively.
ADMA Biologics CFO and Treasurer Brad L. Tade reported a tax-related share disposition tied to restricted stock units (RSUs). On the transaction date, 6,479 shares of common stock were withheld by the company at $16.32 per share to satisfy mandatory tax withholding when RSUs vested, and this was not an open market sale. After this withholding, Tade directly owned 232,940 shares of common stock, including multiple blocks of unvested RSUs granted between June 2023 and February 2025 that will settle into shares over time if service conditions are met.
ADMA Biologics President and CEO Adam S. Grossman reported a mix of option exercise and share sales. On February 17, 2026, he exercised a stock option for 15,000 shares at $5.40 per share, converting it into 15,000 shares of common stock. He then sold a total of 21,000 common shares in open-market transactions at $16.08 per share under a Rule 10b5-1 trading plan.
After these transactions, he directly holds 2,284,379 common shares. He also has indirect holdings of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC. Footnotes note multiple unvested RSU awards granted between 2022 and 2026 that vest over four years and settle in common stock, plus previously acquired shares reflecting prior RSU vesting and purchases.
Fidelity Brokerage Services submitted a Form 144 reporting planned sales of Common Stock tied to option exercises and restricted stock unit vesting. The notice lists proposed sales of 60,000 and 125,000 shares from option exercises and 13,014 and 10,986 shares from RSU vesting.
The filing also records recent dispositions of 21,000 shares on 12/15/2025 for $415,590 and 21,000 shares on 11/19/2025 for $336,000.
Invesco Ltd. filed an amended Schedule 13G reporting beneficial ownership of 11,785,202 shares of ADMA Biologics Inc common stock, representing 5.0% of the class as of 12/31/2025. Invesco reports sole voting power over 11,085,226 shares and sole dispositive power over 11,785,202 shares.
The shares are held of record by clients of Invesco’s investment adviser subsidiaries, including Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC, with no single individual having more than 5% economic ownership. Invesco certifies the position is held in the ordinary course of business and not to influence control of ADMA.
ADMA Biologics director Jerrold B. Grossman received new equity awards. On February 9, 2026, he was granted 10,690 restricted stock units of common stock at $0, which vest in two equal installments over one year, subject to continued service.
He was also granted stock options for 17,730 shares of common stock at a $16.37 exercise price, with these options vesting in twelve equal monthly installments over one year. Following the grant, he directly beneficially owned 488,884 shares of common stock, including previously granted RSUs, and held additional indirect interests through an LLC, a trust, a foundation, and his spouse.
ADMA Biologics COO and SVP, Compliance Kaitlin M. Kestenberg-Messina reported new equity awards. On February 9, 2026, she received 91,631 shares of common stock as restricted stock units at $0 per share and a stock option for 144,230 shares with a $16.37 exercise price.
The RSUs vest quarterly on each annual anniversary of the grant date over four years under the 2022 Equity Compensation Plan, subject to continued service. The option vests over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting monthly until becoming fully vested on February 9, 2030. Following these grants, she beneficially owns 580,321 shares of common stock and 144,230 stock options, all held directly.
ADMA Biologics President and CEO Adam S. Grossman reported new equity awards. On February 9, 2026, he acquired 282,529 shares of common stock in the form of restricted stock units granted at $0 and 444,711 stock options with a $16.37 exercise price.
The RSUs vest quarterly over four years under ADMA’s 2022 Equity Compensation Plan, subject to his continued service. The options also vest over four years, with 25% vesting on the one‑year anniversary and the remaining 75% vesting monthly until fully vested on February 9, 2030. After these awards, he directly beneficially owns 2,290,379 shares of common stock and also has indirect ownership of additional ADMA shares through Areth, LLC and Hariden, LLC.
ADMA Biologics director Young Kwon reported new equity awards. On February 9, 2026, he received 10,690 shares of common stock in the form of restricted stock units granted at $0, which vest in two equal installments over one year, subject to continued service. He also received a stock option to buy 17,730 shares of common stock at an exercise price of $16.37 per share, vesting in twelve equal monthly installments and becoming fully vested on February 9, 2027. After these awards, he directly holds 263,020 shares of common stock, including RSUs, and 17,730 stock options.